General
Preferred name
ZALCITABINE
Synonyms
2',3'-dideoxycytidine ()
DIDEOXYCYTIDINE ()
ddC ()
NSC 606170 ()
Ro 24-2027/000 ()
NSC 606170, Ro 24-2027/000 ()
Zalcitabine (dideoxycytidine,ddc) ()
Ro-24-2027-000 ()
Zalcitabina ()
Hivid ()
Ddc (ddc) ()
Ro-24-2027000 ()
RO-24-2027/000 ()
Ro-242027000 ()
NSC-606170 ()
P&D ID
PD001308
CAS
7481-89-2
Tags
available
prodrug
drug
Approved by
FDA
First approval
1992
Drug indication
Human immunodeficiency virus infection
HIV infection
Drug Status
withdrawn
approved
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
zalcitabine is a nucleoside analog reverse transcriptase inhibitor (NRTI) antiretroviral drug. Chemically it is an is an analogue of pyrimidine and is a derivative of endogenous deoxycytidine.
(GtoPdb)
DESCRIPTION
Zalcitabine is a potent nucleoside analogue reverse transcriptase inhibitor used in the treatment of HIV infection.
PRICE
29
DESCRIPTION
Zalcitabine is a nucleoside analog HIV reverse transcriptase inhibitor. In cells, it is phosphorylated to the active triphosphate form, ddCTP, which acts as a substrate for HIV reverse transcriptase. It incorporates into viral DNA where it terminates chain elongation when the missing hydroxyl group is encountered.
(Enamine Bioactive Compounds)
DESCRIPTION
Nucleoside analog; reverse transcriptase inhibitor; antiviral
(LOPAC library)
DESCRIPTION
Zalcitabine (Dideoxycytidine)(Dideoxycytidine;ddC; 2', 3'-Dideoxycytidine) is a nucleoside analog reverse transcriptase inhibitor (NRTI); At low concentrations, It can potently inhibit HIV replication by binding to reverse transcriptase terminated synthesis of viral DNA chain.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
8
Organisms
6
Compound Sets
32
Cayman Chemical Bioactives
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Concise Guide to Pharmacology 2025/26
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine Bioactive Compounds
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
LOPAC library
MedChem Express Bioactive Compound Library
NIH Clinical Collections (NCC)
NPC Screening Collection
Prestwick Chemical Library
Probe Miner (suitable probes)
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
Withdrawn 2.0
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
91
Molecular Weight
211.1
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
2
Rotatable Bonds
2
Ring Count
2
Aromatic Ring Count
1
cLogP
-0.5
TPSA
90.37
Fraction CSP3
0.56
Chiral centers
2.0
Largest ring
6.0
QED
0.69
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
Reverse Transcriptase
MOA
viral reverse transcriptase inhibitor
nucleoside reverse transcriptase inhibitor
Target
Human immunodeficiency virus type 1 reverse transcriptase
HIV
Indication
human immunodeficiency virus (HIV-1)
ATC
J05AF03
Therapeutic Class
Anti-HIV Agents
Pathway
Anti-infection
Microbiology/virology
Proteases/Proteasome
Source data
